Catalyst Wire Dossier Catalyst Wire Dossier

Ipromlimab

ipromlimab
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ipromlimab, covering 2026-01-28 to 2026-01-28. Get the full timeline:

Most recent: Clinical Trial Update: Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

See pricing